Point-of-Care Diagnostics Devices Patent Landscape Analysis Report 2026 Edition

Point-of-Care Diagnostics Devices Market Size, Growth Trends, and Industry Outlook

Point-of-care diagnostics devices deliver laboratory-grade results at the patient location within minutes. Demand spans emergency departments, physician offices, pharmacies, community health programmes and homes. Clinicians use these devices for triage, treatment initiation and chronic disease monitoring, and payers favour shorter diagnostic pathways. Regulatory frameworks such as CLIA waivers and over-the-counter authorisations continue to widen the range of settings where testing takes place.

Market growth is driven by the demand for rapid diabetes, cardiac and infectious disease testing outside central laboratories. The International Diabetes Federation estimates 589 million adults lived with diabetes in 2024, which keeps glucose and HbA1c devices in continuous demand. The WHO reported 10.8 million new tuberculosis cases in 2023, and that burden sustains purchases of near-patient molecular platforms in high-incidence countries.

North America holds the leading share of device demand because reimbursement, CLIA-waived test menus and retail pharmacy testing are well established. A 2024 FDA authorisation for a finger-stick hepatitis C RNA test shows how regulators now accept single-visit test-and-treat models, which raises device placements in community clinics. Asia Pacific records the fastest unit growth as national programmes in India and China fund decentralised screening, and local manufacturers add price-competitive lateral flow and glucose products. The growth rate reflects a mature glucose segment offset by faster expansion in molecular and cardiac devices.

Read more about this report - Request a Free Sample

Point-of-Care Diagnostics Devices Patent Filing Trends and Innovation Activity

Patent filings for point-of-care diagnostics devices rose sharply during 2020 and 2021 as manufacturers filed on rapid antigen and compact molecular systems. Filing volume stayed above pre-2020 levels in 2023 and 2024, as companies shifted claims toward multiplex panels, sample-to-answer cartridges and home-use designs.

The dataset covers about 26,000 patent families, with peak filing years in 2021 and 2022. Granted patents reached roughly 3,200 in 2025, and the United States, China and the European Patent Office account for most of the grants.

Demand for decentralised testing in chronic disease and infection control translates directly into continuing filings on cartridge design, assay chemistry and connected readers.

Scope of the Point-of-Care Diagnostics Devices Patent Landscape Analysis Report

The report analyses patents and published applications covering point-of-care diagnostics devices, including lateral flow strips, microfluidic cartridges, electrochemical sensors, rapid molecular analysers and optical or smartphone readers. Claims on assay reagents, sample collection hardware and device software are included when tied to a near-patient format.

Coverage extends from 2010 to 2025 and tracks filings, grants, legal status and citation links by family. Assignee ownership is normalised for subsidiaries and acquired entities, for example Alere assets under Abbott and LumiraDx technology under Roche.

The analysis profiles diagnostic manufacturers, glucose and cardiac meter makers, university spin-outs and contract developers, and maps their positions by technology, application and jurisdiction.

Global Point-of-Care Diagnostics Devices Patent Landscape Analysis

Point-of-Care Diagnostics Devices Patent Filing Trend Analysis

Estimated annual growth in global family filings averaged 7 to 9 percent during 2020-2024, led by rapid molecular amplification and multiplex cartridge designs. Pandemic-era antigen and PCR programmes pulled forward inventive activity, and several companies kept the resulting platforms in development for respiratory, sexually transmitted and bloodborne infections.

Chinese applicants contributed a rising share of new filings, especially for lateral flow, chemiluminescence and compact microfluidic devices. Filings on smartphone readers, artificial intelligence-assisted interpretation and connected data management grew faster than the overall rate, reflecting the push toward home use and remote clinical oversight.

Leading Companies and Assignee Analysis in the Point-of-Care Diagnostics Devices Patent Landscape

Geographic Analysis of Point-of-Care Diagnostics Devices Patent Activity

The report assesses patent activity across major jurisdictions, including:

• United States
• Europe
• China
• Japan
• South Korea
• India
• International and WIPO filings

The United States leads in filing volume and in grants for point-of-care diagnostics devices, supported by CLIA-waived pathways and a large commercial analyser base. China ranks second on application counts, driven by domestic diagnostic manufacturers and provincial screening programmes. Europe follows, with the European Patent Office receiving filings from Germany, Switzerland, the Netherlands and the United Kingdom.

Read more about this report - Request a Free Sample

Point-of-Care Diagnostics Devices Technology Segmentation and Innovation Areas

The report segments patent activity across the following technology areas:

• Lateral flow immunoassay chemistry and labels
• Microfluidic cartridges and lab-on-chip architecture
• Rapid molecular amplification and isothermal assays
• Electrochemical and optical biosensors
• Connected readers, smartphone readout and data management

Among these, lateral flow immunoassay and microfluidic cartridge designs account for the largest share of families, because they apply across infectious disease, cardiac and women's health devices.

Competitive Landscape and Emerging Trends in the Point-of-Care Diagnostics Devices Market

Abbott and Roche hold the broadest portfolios, with Siemens Healthineers, Becton Dickinson and Danaher following. Abbott concentrates on cartridge analysers and rapid tests, Roche on molecular and cardiac meters, and Danaher on GeneXpert-based molecular testing. Smaller developers such as Visby Medical and Sherlock Biosciences file narrower families on home-use molecular formats and are frequent licensing and acquisition targets.

Companies are focusing on:

• Rapid antigen and lateral flow assay chemistry
• Single-use microfluidic cartridges for sample-to-answer testing
• CLIA-waived molecular analysers for clinics and pharmacies
• Finger-stick whole blood sampling and sample preparation
• Handheld cardiac, coagulation and blood gas analysers
• Home-use multiplex tests for sexually transmitted and respiratory infections
• Connectivity, cloud data transfer and result interpretation software

Emerging innovation themes include multiplex molecular cartridges for home use, CRISPR-based detection chemistry, smartphone-readable lateral flow tests, wearable biosensors for sweat and interstitial fluid, and artificial intelligence-assisted result interpretation. Whole blood biomarkers for concussion and sepsis triage represent a further area of new filings.

Strategic Insights from the Point-of-Care Diagnostics Devices Patent Landscape

Portfolios in point-of-care diagnostics devices are built around installed analyser platforms, with consumables and cartridges generating recurring revenue. Large assignees protect reader hardware and cartridge interfaces, and they extend assay menus through acquisitions such as the 2024 purchase of LumiraDx technology by Roche. Freedom-to-operate review is most active around CRISPR detection, isothermal amplification and home-use sample collection.

Technology segments, assignee positions and jurisdiction trends in point-of-care diagnostics devices are mapped to give actionable intelligence supporting:

• Intellectual property strategy
• R&D prioritisation
• Competitive benchmarking
• Technology scouting
• Licensing evaluation
• Partnership assessment
• Investment analysis
• Market entry planning
• Portfolio expansion strategy

Research Methodology for the Point-of-Care Diagnostics Devices Patent Landscape Analysis

Patent data were collected from the USPTO, the European Patent Office, the China National Intellectual Property Administration, the Japan Patent Office, WIPO PATENTSCOPE and Espacenet. Queries combined CPC classes G01N33/543, G01N33/558, G01N27/327, C12Q1/68, B01L3/00 and A61B5/145 with keyword strings for point-of-care, near-patient, handheld, cartridge and rapid test formats.

Records were screened for relevance, and applications were consolidated into simple families to remove duplicates across jurisdictions. Assignee names were harmonised for subsidiaries, mergers and acquisitions, and each family was classified by technology, application, device format and jurisdiction.

The market side draws on regulatory filings from the US FDA and the European Commission database, company annual reports, clinical trial registries and peer-reviewed literature. Patent trends were cross-checked against product launches, CLIA waiver announcements and licensing transactions.

Related Reports

Point of Care Coagulation Testing Devices Market

Tissue Diagnostics Market Size

Companion Diagnostics Patent Landscape Analysis Report